Form 4: Aquestive CCO Granted 25,000 Restricted Shares

Aquestive Therapeutics' Chief Commercial Officer, Sherry Korczynski, received a grant of 25,000 restricted common shares as part of her compensation.

Summary

• Sherry Korczynski, the Chief Commercial Officer of Aquestive Therapeutics, Inc. (AQST), acquired 25,000 shares of Common Stock.
• The transaction date for this acquisition was August 14, 2025.
• The shares acquired are restricted stock, granted at a price of $0, indicating an equity award.
• These restricted shares will vest in three annual installments: 25% on the first installment, 25% on the second installment, and 50% on the third installment.
• Following this transaction, Ms. Korczynski beneficially owns 181,858 shares of Common Stock.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a key executive aligns management's interests with long-term shareholder value, which is a positive signal for corporate governance and stability, though not a major catalyst.

Positives

• The grant of restricted stock aligns the Chief Commercial Officer's interests with long-term shareholder value, incentivizing performance.
• Equity compensation is a standard practice for retaining and motivating key executives.

Future Outlook

The restricted stock grant includes a vesting schedule over three annual installments, indicating a future commitment and incentive for the Chief Commercial Officer's continued performance and retention.

Industry Context

The grant of restricted stock to a Chief Commercial Officer is a common and standard practice within the pharmaceutical and biotechnology industries for executive compensation, aiming to align management incentives with company performance and shareholder returns.

Comparison to Industry Standards

• Equity compensation, such as restricted stock grants, is a widely adopted practice across publicly traded companies, particularly in the technology and healthcare sectors, to attract, retain, and motivate key executives.
• The vesting schedule of 25%, 25%, and 50% over three annual installments is a typical structure designed to encourage long-term commitment and performance, comparable to similar incentive plans observed in peer companies within the biopharmaceutical industry.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a key executive with shareholders, potentially leading to better long-term performance.
• Employees (specifically the recipient): Provides significant equity compensation, incentivizing retention and performance.

Next Steps

• Vesting of the restricted stock in three annual installments: 25% on the first, 25% on the second, and 50% on the third.

Key Dates

Recommendation

This Form 4 filing reports a standard equity grant to a Chief Commercial Officer, which is a routine compensation event and does not provide sufficient new information to alter an investment thesis. It indicates management alignment but is not a catalyst for a strong buy or sell recommendation on its own.

Keywords

Aquestive Therapeutics, AQST, Form 4, insider transaction, restricted stock, equity grant, executive compensation, Sherry Korczynski